Physician profile
Wendell Porter
NPI 1487624623
$1,190.29
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $848 · 2022: $342.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $336.14 | 2021-2022 | |
| Amarin Pharma, INC. | $299.01 | 2021-2022 | |
| Glaxosmithkline, LLC. | $189.29 | 2021-2022 | |
| Amgen INC. | $67.14 | 2021 | |
| Astellas Pharma US INC | $51.98 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $39.85 | 2021 | |
| Esperion Therapeutics, INC. | $34.67 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.18 | 2021 | |
| Merck Sharp & Dohme LLC | $26.93 | 2021 | |
| Lilly USA, LLC | $26.85 | 2021 | |
| Abbvie INC. | $26.16 | 2021 | |
| Radius Health, INC. | $18.24 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.19 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.15 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.51 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendell Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.